Immune-Stimulating Antibody Conjugation (ISAC)

As a leading service provider focused on drug development, BOC Sciences has been supporting customers at the forefront of drug conjugates. Immune-stimulating antibody conjugate (ISAC) is a new immunotherapy. It has both the targeting accuracy of antibody and the innate and adaptive nature of the immune system. ISAC can activate immune killing and treatment sensitivity, and has the ability to transform cold tumors into immune hot tumors by regulating immune stimulation and microenvironment. We provide Immune-stimulating antibody conjugation service to meet your unique project needs.

Find out more with Drug Conjugation Services.

Introduction

ISAC consists of three main components: tumor targeting antibodies, non degradable linkers, and proprietary immune stimulants for activating the innate immune system. ISAC can activate and recruit bone marrow cells through targeting a single marker on the tumor cells to produce a new immune response. Through releasing cytokines and chemokines, attracting related immune cells and reducing the activation threshold of immune response, bone marrow cells which are activated begin the feedforward cycle. This will reprogram the tumor microenvironment, and then trigger an immune response which can be adaptive against the tumor, so as to provide a lasting response for patients.

• Function

ISAC is similar to undercover entering tumors to activate innate immunity and inform external immune cells at the same time. The following table lists the three functions and their roles of ISAC.

Table 1 Three functions and their roles of ISAC

• Advantage

The advantages of ISAC are mainly reflected in three aspects: action mechanism, target selection and endocytosis. The specific contents are shown in Table 2.

Table 2 Three advantages of ISAC

Our Services

• Selection and screening of ligands
• Optimization of conjugation methods and linkers
• Immune-stimulating antibody conjugation

Application

ISAC has achieved complete tumor regression and lasting anti-tumor immunity in a variety of tumor models. ISAC plays its role mainly by coupling tumor targeted monoclonal antibodies with immune agonists through non cleavable linkers. Studies have reported that APCs can be activated and induced to mature in vitro through the effect of rituximab T785-ISAC. The functional Fc fragments of TLR agonists and antibodies play vital role in activating APCs, indicating the significance of FcγR in the absorption and internalization of ISAC. The activation of APCs can be induced by ISAC through the joint action of FcγR and TLR. ISAC enhances the function of anti-tumor myeloid cells through the synergistic activity of two signal pathways. In addition, by inducing a strong pro-inflammatory environment, ISAC could accumulate activated myeloid APCs and increase the number of local cytokines and chemokines. Studies also have found the cured mice were further protected when re-implanted into the tumor, indicating that ISAC has a significant anti-refractory large tumor effect in the presence of B cells, T cells and NK cells.^[1]

Fig.1 Graphical depiction of the two-step T785-ISAC conjugation reaction.

Our Advantages

• Different ISAC structures and batch development experience
• Various conjugation methods
• A wide range of characteristic analysis
• Data analysis, detailed report with results and discussion